UH Urology Institute Announces Dr Irina Jaeger Designation as UroLift® Center of Excellence
January 08, 2019
Designation Recognizes Dr. Irina Jaeger’s Commitment to Exemplary Care, Deep UroLift Experience
University Hospitals Urology Institute today announced that Irina Jaeger, MD, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Jaeger has achieved a high level of training and experience with the UroLift System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with benign prostatic hyperplasia (BPH).
“I’m proud to be recognized as a UroLift Center of Excellence,” Dr. Jaeger said. “The UroLift System can not only better the lives of men suffering from enlarged prostate symptoms, but also improve the lives of their partners. I hear from many spouses who are just as excited about the results of the treatment as their husbands. Unlike most other BPH treatment options, the UroLift System preserves sexual function.” Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.
Five-year data from a randomized study shows the UroLift System offers not only rapid improvement, but also durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial, BPH6, demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy and is superior to TURP at preserving sexual function and offering a more rapid recovery.Medication is often the first-line therapy for BPH, but relief can be inadequate and temporary. Medication side effects can include sexual dysfunction, dizziness and headaches, prompting many patients to quit taking the medication. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they also can leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.
About the UroLift SystemNeoTract’s FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.
UH’s vision is “Advancing the science of health and the art of compassion,” and its mission: “To Heal. To Teach. To Discover.” Follow UH on Facebook @UniversityHospitals and Twitter @UHhospitals.
1. Roehrborn et al. Can J. Urology 2017
2. Sonksen et al J Urology 2016